Shots:

• The companies terminated their collaboration that centered around bintrafusp alfa as the drug failed to show potential in INTR@PID Lung 037 study as the 2L treatment for metastatic BTC
• The termination followed a decision made by the two companies to discontinue the development of bintrafusp alfa as a 1L therapy for patients with stage IV NSCLC and high expression of PD-L1
• IDSM board recommended the termination of the P-III study in which bintrafusp + Keytruda was not likely to meet its 1EPs of PFS

  | Ref: Merck KGaA | Image: CHEManager